Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:

Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate

This article was originally published in PharmAsia News

  • News

Executive Summary

Tacere Therapeutics has entered into a strategic alliance with Tokyo-based Oncolys BioPharma to develop its lead RNA interference-based candidate for treatment of hepatitis C, the companies announced June 21

You may also be interested in...



Pfizer Boosts RNAi Interest With Sigma-Aldrich Licensing Agreement

Deal comes on the heels of September agreement for potential RNAi therapy for macular degeneration.

Alnylam, Nastech Take Different IP Approaches To Pandemic Flu RNAi Therapies

Alnylam predicts companies will come knocking on its door to license its intellectual property in the field.

Yes, Sirna: Merck Inks $1.1 Bil. Deal For RNAi Firm

Merck continues acquisition spurt with purchase of San Francisco biotech.

Table

View full table

Tags:
UsernamePublicRestriction

Register

SC066308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By